PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

S. Loibl, O. Metzger, S. J. Mandrekar, C. Mundhenke, S. Seiler, P. Valagussa, A. DeMichele, E. Lim, D. Tripathy, E. P. Winer, C. Huang, L. Carey, P. Francis, K. D. Miller, M. P. Goetz, A. Prat, S. Loi, I. Krop, L. Gianni, E. M. Ciruelos

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)viii121
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this